Looking into anti-angiogenic gene therapies for disorders of the eye

Drug Discovery Today

Volumn 6, Issue 22, 2001, Pages 1171-1175

  Rasmussen, Henrik S ^a   Rasmussen, Camilla S ^a   Durham, Rebecca G ^a   King, C Richter ^a   Wei, Lisa ^a  

^a GenVec   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PRINOMASTAT; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; BLINDNESS; DIABETIC RETINOPATHY; EYE DISEASE; GENE THERAPY; GENE TRANSFER; HUMAN; MOUSE; NONHUMAN; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW;

EID: 0035889668     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)02034-7     Document Type: Review

References (46)

1. Epidemiology of age-related macular degeneration
2. Treatment of diabetic retinopathy
3. Diabetic retinopathy: a further study of prognosis for vision
4. How effective are treatments for diabetic retinopathy?
5. Neovascular (exudative) age-related macular degeneration
6. Age-related macular degeneration
7. Age-related macular degeneration and blindness due to neovascular maculopathy
8. Vascular endothelial growth factor and ocular neovascularization
9. Treatment of diabetic retinopathy
10. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
11. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma
12. Inhibition of vascular endothelial growth factor activity by an endogenously endcoded soluble receptor
13. Anti-angiogenesis and tumor metastasis
14. Interferon α-2a is ineffective for patients with CNV secondary to age-related macular degeneration: results of a prospective, randomized, placebo-controlled clinical trial
15. The angiogenesis inhibitor, Prinomastat (AG3340) in the treatment of age-related macular degeneration: study design and baseline characteristics
16. Mechanisms of intraocular inflammation
17. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy
18. Anti-VEGF therapy in patients with exudative age-related macular degeneration
19. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
20. Ocular gene therapy: experimental studies and clinical possibilities
21. Adenovirus vector mediated in vivo gene transfer into adult murine retina
22. Evaluation of recombinant adeno-associated virus as gene transfer vector for the retina
23. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector
24. Gene therapy restores vision in a canine model of childhood blindness
25. Gene therapy for ocular disease
26. Enhanced perspective: unraveling immune privilege
27. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization
28. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expression secretable endostatin
29. Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model
30. Commentary. PEDF: raising both hopes and questions in controlling angiogenesis
31. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells
32. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity
33. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine-protease inhibitor gene-family
34. Structural and comparative analysis of the mouse gene for pigment epithelium-derived factor (PEDF)
35. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurothropic activity
36. Pigment epithelium-derived factor protects cultured cerebellar granule cells against glutamate-induced neurotoxicity
37. Pigment epithelium-derived factor (PEDF) differentially protects immature but not mature cerebellar granule cells against apoptotic cell death
38. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis
39. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization
40. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment
41. Prevention of ischemia-induced retinopathy by the natural ocular anti-angiogenic agent pigment epithelium-derived factor
42. In vivo expression of pigment epithelium-derived factor by adenovirus-mediated gene therapy
43. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization
44. Adenovirus gene delivery for the treatment of ocular diseases
45. Transgenic mice with increased expression of vascular endothelial growth factor in the retina